Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.

Ciao-Sin ChenEllen M Lavoie SmithKathleen A StringerN Lynn HenryDaniel Louis Hertz

Published in: Breast cancer research and treatment (2022)

Our findings suggest that sensory and motor CIPN co-occur and may not have differentiating metabolic biomarkers. These findings need to be validated in larger cohorts of patients treated with paclitaxel and other neurotoxic agents to determine the optimal approach to predict, prevent, and treat CIPN and improve patients' outcomes.

Keyphrases

chemotherapy induced
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
computed tomography
type diabetes
magnetic resonance
patient reported outcomes
metabolic syndrome
contrast enhanced
patient reported